Lonza Group Announces Results Of The 2017 Annual General Meeting – All Motions Proposed By Board Of Directors Accepted
- 235 shareholders attended, representing 59.96% of the share capital
- Shareholders re-elected all existing members of the Board of Directors except for Thomas Ebeling, who did not stand for re-election, and approved the new election of Albert M. Baehny
- Rolf Soiron was re-elected as Board Chairperson for another year
- A dividend of CHF 2.75 per share will be paid out as from 3 May 2017
Basel, Switzerland, 25 April 2017 – Today’s Annual General Meeting of Lonza Group Ltd, led by the Chairperson of the Board of Directors, Rolf Soiron, was attended by 235 shareholders. They represented 59.96% of the share capital.
The Board members standing for re-election (Rolf Soiron, Patrick Aebischer, Werner Bauer, Jean-Daniel Gerber, Christoph Mäder, Barbara Richmond, Margot Scheltema, Juergen Steinemann and Antonio Trius) were all elected for a further term in office of one year. Thomas Ebeling did not stand for re-election. The shareholders also elected Albert M. Baehny as a new member of the Board. The Annual General Meeting re-elected Rolf Soiron as Chairperson of the Board of Directors for a further term in office of one year, as well as the three acting members of the Nomination and Compensation Committee.
The shareholders strongly supported all other motions proposed by the Board of Directors, including among others the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.
A dividend of CHF 2.75 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out from 3 May 2017.
The shareholders also supported the increase of the share capital by the issuance of up to 22,000,000 fully paid registered shares to raise gross proceeds in the amount of approximately CHF 2.3 billion by way of a rights offering, the reintroduction of authorized capital in the amount of CHF 7,500,000, and an increase of the existing conditional capital from currently CHF 5,029,860 to CHF 7,500,000.
For further information, please see the short-form minutes of the Lonza Annual General Meeting under the following link (select “Annual General Meeting 2017”).
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Lonza Contact Details
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com
Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com
Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com
- Shareholders re-elected all existing members of the Board of Directors except for Thomas Ebeling, who did not stand for re-election, and approved the new election of Albert M. Baehny
- Rolf Soiron was re-elected as Board Chairperson for another year
- A dividend of CHF 2.75 per share will be paid out as from 3 May 2017
Basel, Switzerland, 25 April 2017 – Today’s Annual General Meeting of Lonza Group Ltd, led by the Chairperson of the Board of Directors, Rolf Soiron, was attended by 235 shareholders. They represented 59.96% of the share capital.
The Board members standing for re-election (Rolf Soiron, Patrick Aebischer, Werner Bauer, Jean-Daniel Gerber, Christoph Mäder, Barbara Richmond, Margot Scheltema, Juergen Steinemann and Antonio Trius) were all elected for a further term in office of one year. Thomas Ebeling did not stand for re-election. The shareholders also elected Albert M. Baehny as a new member of the Board. The Annual General Meeting re-elected Rolf Soiron as Chairperson of the Board of Directors for a further term in office of one year, as well as the three acting members of the Nomination and Compensation Committee.
The shareholders strongly supported all other motions proposed by the Board of Directors, including among others the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.
A dividend of CHF 2.75 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out from 3 May 2017.
The shareholders also supported the increase of the share capital by the issuance of up to 22,000,000 fully paid registered shares to raise gross proceeds in the amount of approximately CHF 2.3 billion by way of a rights offering, the reintroduction of authorized capital in the amount of CHF 7,500,000, and an increase of the existing conditional capital from currently CHF 5,029,860 to CHF 7,500,000.
For further information, please see the short-form minutes of the Lonza Annual General Meeting under the following link (select “Annual General Meeting 2017”).
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Lonza Contact Details
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com
Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com
Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com